Name: Pomalidomide-PEG<SUB>6</SUB>-NH<SUB>2</SUB> hydrochloride
Brand: ALDRICH
Price: 498 USD
Availability: InStock

ligand

pomalidomide

assay

≥98%

form

powder

reaction suitability

reactivity: carboxyl reactive
reagent type: ligand-linker conjugate

functional group

amine

storage temp.

2-8°C

SMILES string

O=C(C(CC1)N(C2=O)C(C3=C2C=CC=C3NC(COCCOCCOCCOCCOCCOCCN)=O)=O)NC1=O.Cl

InChI

1S/C27H38N4O11.ClH/c28-6-7-37-8-9-38-10-11-39-12-13-40-14-15-41-16-17-42-18-23(33)29-20-3-1-2-19-24(20)27(36)31(26(19)35)21-4-5-22(32)30-25(21)34;/h1-3,21H,4-18,28H2,(H,29,33)(H,30,32,34);1H

InChI key

LLMKJSMLQBRFGR-UHFFFAOYSA-N

Related Categories

Chemical Biology

Protein Degrader Building Blocks

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	901830	901516	901513
Sigma-Aldrich 901832 Pomalidomide-PEG₆-NH₂ hydrochloride	Sigma-Aldrich 901830 Pomalidomide-PEG₄-NH₂ hydrochloride	Sigma-Aldrich 901516 Pomalidomide-PEG₁-NH₂hydrochloride	Sigma-Aldrich 901513 Pomalidomide-PEG₂-NH₂ hydrochloride
assay ≥98%	assay ≥95%	assay ≥95%	assay ≥95%
functional group amine	functional group -	functional group amine	functional group amine
reaction suitability reactivity: carboxyl reactive, reagent type: ligand-linker conjugate	reaction suitability -	reaction suitability reactivity: carboxyl reactive, reagent type: ligand-linker conjugate	reaction suitability reactivity: carboxyl reactive, reagent type: ligand-linker conjugate
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C
form powder	form powder or crystals	form powder or crystals	form powder or crystals
ligand pomalidomide	ligand pomalidomide	ligand pomalidomide	ligand pomalidomide

Application

Protein degrader builiding block Pomalidomide-PEG₆-NH₂ (HCl salt) enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting ligand and a PEGylated crosslinker with pendant amine for reactivity with a carboxyl group on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a pendant amine, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Automate your CRBN-PEG based PROTACs with Synple Automated Synthesis Platform (SYNPLE-SC002)

Other Notes

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Portal: Building PROTAC^® Degraders for Targeted Protein Degradation

Targeted Protein Degradation by Small Molecules

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Impact of linker length on the activity of PROTACs

Legal Information

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

related product

Product No.

Description

Pricing

901490

(S,R,S)-AHPC hydrochloride, ≥97%

901487

(S,S,S)-AHPC hydrochloride, ≥97%

901488

(S,R,S)-AHPC-PEG₂-NH₂ hydrochloride, ≥95%

901493

(S,R,S)-AHPC-PEG₁-NH₂ hydrochloride, ≥95%

901494

N-Methylated pomalidomide, ≥98%

901495

Pomalidomide-PEG₃-NH₂ hydrochloride, ≥95%

901496

Pomalidomide-C₆-CO₂H, ≥98%

901500

Pomalidomide-C₃-CO₂H, ≥95%

901503

(S,R,S)-AHPC-PEG₁-Alkyne, ≥95%

901511

(S,R,S)-AHPC-PEG₃-NH₂ hydrochloride, ≥95%

901504

Pomalidomide-PEG₃-CO₂H, ≥95%

901517

(S,R,S)-AHPC-PEG₂-Alkyne, ≥95%

901516

Pomalidomide-PEG₁-NH₂hydrochloride, ≥95%

901513

Pomalidomide-PEG₂-NH₂ hydrochloride, ≥95%

901523

Pomalidomide-PEG₁-Alkyne, ≥98%

901533

(S,R,S)-AHPC-PEG₃-Alkyne, ≥95%

901534

(S,R,S)-AHPC-C₆-CO₂H hydrochloride

901531

Pomalidomide-PEG₃-Alkyne, ≥95%

901529

Pomalidomide-PEG₂-Alkyne, ≥95%

901527

Pomalidomide-PEG₁-CO₂H, ≥95%

901526

Pomalidomide-PEG₂-CO₂H, 95%

901525

Pomalidomide-C₉-CO₂H, ≥95%

901558

Lenalidomide, ≥95%

901579

t-Boc-N-amido-PEG₁-CH₂CO₂H

901577

t-Boc-N-amido-PEG_2-CH₂CO₂H, ≥95%

901575

t-Boc-N-amido-PEG₃-CH₂CO₂H, ≥95%

901572

Bromo-PEG₂-acid, ≥95%

901568

Bromo-PEG₃-acid

901567

Propargyl-PEG₁-acid, ≥95%

901566

Propargyl-PEG₂-acid

901573

Bromo-PEG₁-acid, ≥95%

901565

Propargyl-PEG₃-acid

901835

Pomalidomide-PEG₆-Alkyne

901834

Pomalidomide-PEG₅-Alkyne, ≥95%

901833

Pomalidomide-PEG₄-Alkyne

901831

Pomalidomide-PEG₅-NH₂hydrochloride

901830

Pomalidomide-PEG₄-NH₂ hydrochloride, ≥95%

901829

Pomalidomide-PEG₆-CO₂H

901828

Pomalidomide-PEG₅-CO₂H, ≥95%

901824

Pomalidomide-PEG₄-CO₂H

901860

(S,R,S)-AHPC-PEG₆-NH₂ hydrochloride, ≥95%

901855

(S,R,S)-AHPC-PEG₅-Alkyne

901851

(S,R,S)-AHPC-PEG₄-Alkyne

901850

(S,R,S)-AHPC-PEG₅-NH₂ hydrochloride

901873

(S,R,S)-AHPC-PEG₆-Alkyne

902659

Amino-PEG6-t-butyl ester

903434

Pomalidomide-PEG₆-butyl azide, ≥95%

903442

Pomalidomide-PEG₆-butyl iodide, ≥95%

903833

Pomalidomide-PEG2-azide

903825

Pomalidomide-PEG1-azide

903957

(S,R,S)-AHPC-PEG1-azide

904651

(S,R,S)-AHPC-PEG₃-azide, ≥95%

904724

Pomalidomide-PEG₂-butyl iodide, ≥95%

904708

Pomalidomide-C₆-PEG₃-butyl iodide, ≥95%

904678

Pomalidomide-PEG3-azide

904686

Pomalidomide-C₆-PEG₃-butyl azide, ≥95%

904813

(S,R,S)-AHPC-PEG2-azide

904821

(S,R,S)-AHPC-C₆-PEG₃-butyl azide, ≥95%

904880

Pomalidomide-C₆-PEG₁-C₃-PEG₁-butyl azide, ≥95%

904872

Pomalidomide-PEG₂-butyl azide, ≥95%

904864

(S,R,S)-AHPC-PEG₆-butyl azide, ≥95%

905178

(S,R,S)-AHPC-C₆-PEG₁-C₃-PEG₁-butyl azide, ≥95%

905275

(S,R,S)-AHPC-PEG₆-butyl amine hydrochloride, ≥95%

905216

(S,R,S)-AHPC-PEG₂-butyl azide, ≥95%

905232

(S,R,S)-AHPC-C₆-PEG₃-butyl amine hydrochloride, ≥95%

905224

Pomalidomide-PEG₆-butyl amine hydrochloride, ≥95%

905208

Pomalidomide-C₆-PEG₃-butyl amine hydrochloride, ≥98%

905399

(S,R,S)-AHPC-PEG₂-butyl chloride

905380

(S,R,S)-AHPC-C₆-PEG₃-butyl chloride, ≥95%

905402

(S,R,S)-AHPC-C₆-PEG₁-C₃-PEG₁-butyl chloride, 95%

906050

Pomalidomide-C₆-PEG₁-C₃-PEG₁-butyl iodide, ≥95%

906123

(S,R,S)-AHPC-PEG₂-butyl amine hydrochloride

907677

(S,R,S)-AHPC-PEG₆-butyl chloride

910023

3,6,9,12,15,18-Hexaoxahexacos-25-ynoic acid

910074

27,27-Dimethyl-25-oxo-3,6,9,12,15,18,26-heptaoxaoctacosanoic acid, ≥95%

911801

AHPC-C₆-PEG₁-C₃-PEG₁-butyl amine hydrochloride, ≥90%

911690

C5 Lenalidomide, ≥95%

911666

Pomalidomide-C₆-NH₂ hydrochloride, ≥95%

911658

Pomalidomide-C₃-NH₂ hydrochloride, ≥95%

911720

C5 Lenalidomide-C₉-NH₂ hydrochloride, ≥95%

911712

C5 Lenalidomine-C₆-NH₂ hydrochloride, ≥95%

911755

C5 Lenalidomide-PEG₅-NH₂ hydrochloride

911704

C5 Lenalidomine-C₃-NH₂ hydrochloride, ≥95%

911739

C5 Lenalidomide-PEG₁-NH₂ hydrochloride, ≥95%

911747

C5 Lenalidomide-PEG₃-NH₂ hydrochloride, ≥95%

911763

C5 Lenalidomide-PEG₁-piperazine hydrochloride, ≥95%

913987

Pomalidomide-C₆-PEG₁-C₃-PEG₁-butyl amine hydrochloride, ≥95%

915572

Pomalidomide-dipiperazine-NH₂ hydrochloride, ≥95%

916536

Pomalidomide-piperazine-pyridine-alkyne-NH₂ hydrochloride

917729

C5 Lenalidomide-piperazine-pyridine-alkyne-NH₂ hydrochloride, ≥95%

917303

C5 Lenalidomide-C₆-PEG₁-C₃-PEG₁-Butyl NH₂ hydrochloride, ≥95%

917052

(S,R,S)-AHPC-C₃-NH₂ hydrochloride, ≥95%

917818

(S,R,S)-AHPC-C₉-NH₂ hydrochloride, ≥95%

917559

(S,R,S)-AHPC-C₆-NH₂ hydrochloride, ≥95%

919357

(S,R,S)-AHPC-PEG₁-piperazine hydrochloride, ≥95%

918350

C5 Lenalidomide-alkyne-piperidine hydrochloride, ≥95%

920746

Pomalidomide-benzyl-piperazine hydrochloride

920754

C5 Lenalidomide-benzyl-piperazine hydrochloride

920789

Pomalidomide-pyridine-PEG₁-piperazine hydrochloride

920797

C5 Lenalidomide-pyridine-PEG₁-piperazine hydrochloride, ≥95%

920800

C5 Lenalidomide-methylamino-PEG1-NH₂ hydrochloride, ≥95%

921300

C5 Lenalidomide-pyrimidine-piperazine-PEG₁-NH₂ hydrochloride, ≥95%

921327

C5 Lenalidomide-PEG₆-Butyl NH₂ hydrochloride, ≥95%

924202

5-Amino-Thalidomide, ≥95%

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000214610

0000098806

0000214610

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Small-Molecule PROTACS: New Approaches to Protein Degradation.

Momar Toure et al.

Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)

The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is

Impact of linker length on the activity of PROTACs.

Kedra Cyrus et al.

Molecular bioSystems, 7(2), 359-364 (2010-10-06)

Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations

Small-Molecule PROTACS: New Approaches to Protein Degradation.

Momar Toure et al.

Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)

The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is

Targeted Protein Degradation: from Chemical Biology to Drug Discovery.

Philipp M Cromm et al.

Cell chemical biology, 24(9), 1181-1190 (2017-06-27)

Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

Articles

Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks are a collection of crosslinker-E3 ligand conjugates with a pendant functional group for covalent linkage to a target ligand.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Pomalidomide-PEG6-NH2 hydrochloride

≥98%

Select a Size

901832-50MG

$498.00

About This Item

Key Documents

Skip To

Properties